Alice Turner

Alice Turner is a Professor of Respiratory Medicine in the School of Applied Health Sciences at the University of Birmingham. She lectures to medical and dental students, engages in clinical teaching at local hospitals, and maintains an active research program with over 190 publications and 64 projects. Her work significantly impacts the fields of chronic obstructive pulmonary disease and alpha-1 antitrypsin deficiency.

Professor Turner's research is centered on chronic obstructive pulmonary disease (COPD) and alpha-1 antitrypsin deficiency (AATD), with expertise in disease mechanisms, exacerbation triggers, and sustainable care models. Her work spans basic science (e.g., cell genomics) to clinical applications (e.g., guideline adherence), emphasizing bacterial colonization in AATD and inhaler sustainability. She has published over 190 research outputs, including systematic reviews and registry-based studies, contributing to international understanding of these conditions.

Her recent publications (2023-2025) reveal a strong focus on interdisciplinary collaboration, integrating microbiome science, genetic epidemiology, and environmental health. Key themes include the role of bacterial colonization in AATD exacerbations, age-dependent clinical characteristics in AATD-COPD, and sustainable inhaler practices. These works often leverage large datasets (e.g., EARCO registry) and address practical challenges in respiratory care, influencing clinical guidelines and patient management strategies globally.

No scientific awards or fellowships were explicitly mentioned in the available information.

Professor Turner actively supervises PhD students on projects including cell-specific genomics in COPD-lung cancer pathogenesis and hypoxia in vascular comorbidities. She leads numerous funded projects, such as:

• Industry-sponsored research with SANOFI, Takeda, and GSK on AATD and inhaler sustainability
• NIHR-funded projects on patient safety and thromboprophylaxis in lung cancer

She collaborates extensively with national and international teams, including the EARCO study group, and participates in initiatives promoting sustainable respiratory medicine through invited talks and industry partnerships.